Chemotherapy in metastatic and locally advanced non-small cell lung cancer

Seminars in Surgical Oncology

Volumn 21, Issue 2, 2003, Pages 98-110

  Spigel, David R ^a,b   Greco, F Anthony ^a  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

^b NONE   (United States)

Author keywords

Advanced; Chemotherapy; Locally advanced; Metastatic; Non small cell lung cancer; NSCLC; Platinum; Radiotherapy; Supportive care; Third generation; Unresectable

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; AE 941; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CELECOXIB; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIRUBICIN; ERLOTINIB; ETOPOSIDE; GEFITINIB; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; METHOTREXATE; MITOMYCIN; NAVELBINE; PACLITAXEL; REBIMASTAT; THALIDOMIDE; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; VINCA ALKALOID; VINDESINE;

ALOPECIA; ANEMIA; ARTHRALGIA; ASTHENIA; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DYSESTHESIA; FATIGUE; FEVER; FLUID RETENTION; HEMOPTYSIS; HUMAN; HYPERSENSITIVITY; LEUKOPENIA; LUNG NON SMALL CELL CANCER; METASTASIS; MYALGIA; NAIL DISEASE; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OTOTOXICITY; PATIENT SELECTION; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SKIN TOXICITY; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS;

EID: 0141962482     PISSN: 87560437     EISSN: None     Source Type: Journal    
DOI: 10.1002/ssu.10027     Document Type: Review

References (62)

1. Bunn P, Kelly K: New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future direction. Clin Cancer Res 1998;5:1087.
2. NSCLCCG: Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 1995;311(7010):899-909.
3. Thongprasert S, Sanguanmitra P, Juthapan W, et al: Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: best supportive care (BSC) versus BSC plus chemotherapy. Lung Cancer 1999;24:17-24.
4. Cartei G, Cartei F, Cantone A, et al: Cisplatin-cyclophosphamide-mitomycin combination chemotherapy with supportive care-versus supportive care alone for treatment of metastatic non-small-cell lung cancer. J Natl Cancer Inst 1993;85:794-800.
5. ASCO: Clinical practice guidelines for the treatment of unresectable non-small cell lung cancer. Clin Oncol 1997;15:2996.
6. Cullen M: Lung Cancer-4: Chemotherapy for non-small cell lung cancer: the end of the beginning. Thorax 2003;58:352-356.
7. Rapp E, Pater JL, Willan A, et al: Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer-report of a Canadian multicenter randomized trial. Clin Oncol 1988;6:633-641.
8. Cullen MH, Billingham LJ, Woodroffe CM, et al: Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol 1999;17:3188-3194.
9. Stephens R, Fairlamb D, Gower N, et al: The big lung trial (BLT): determining the value of cisplatin-based chemotherapy for all patients with non-small cell lung cancer (NSCLC). Preliminary results in the supportive care setting. Proceedings of the 38th Annual Meeting of the American Society of Clinical Oncology; 2002; Orlando.
10. Ranson M, Davidson N, Nicolson M, et al: Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 2000;92:1074-1080.
11. Bunn PA: Chemotherapy for advanced non-small-cell lung cancer: who, what, when, why?. J Clin Oncol 2002;20(18 Suppl):23S-33S.
12. LeChevalier T, Brisgand D, Douillard J, et al: Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 1994;12:360-367.
13. Langer CJ, Leighton JC, Comis RL, et al: Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol 1995;13:1860-1870.
14. Bonomi P, Kim K, Fairclough D, et al: Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 2000;18:623-631.
15. Giaccone G, Splinter TA, Debruyne C, et al: Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 1998;16:2133-2141.
16. Kunitoh H, Watanabe K, Ohashi Y, et al: Preliminary results of a randomized phase III trial of docetaxel (D) and cisplatin (P) versus vindesine (V) and P in stage IV non small cell lung cancer (NSCLC). Proceedings of the 37th Annual Meeting of the American Society of Clinical Oncology; 2001; San Francisco.
17. Cardenal F, Lopez-Cabrerizo MP, Anton A, et al: Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 1999;17:12-18.
18. Crino L, Calandri C, Maestri A, et al: Gemcitabine and cisplatin combination in early-stage non-small-cell lung cancer. Oncology (Huntingt) 2001;15(3 Suppl 6):40-42.
19. Melo M, Barradas P, Costa A, et al: Results of a randomized phase III trial comparing 4 cisplatin (P)-based regimens in the treatment of locally advanced and metastatic non-small cell lung cancer (NSCLC): mitomycin/vinblastine/cisplatin (MVP) is no longer a therapeutic option. Proceedings of the 37th Annual Meeting of the American Society of Clinical Oncology; 2002; Orlando.
20. Rudd R, Gower N, James L, et al: Phase III randomized comparison of gemcitabine and carboplatin (GC) with mitomycin, ifosfamide and cisplatin (MIP) in advanced non-small cell lung cancer (NSCLC). Proceedings of the 37th Annual Meeting of the American Society of Clinical Oncology; 2002; Orlando.
21. Masuda N, Fukuoka M, Negoro S, et al: Randomized trial comparing cisplatin (CDDP) and irinotecan (CPT-11) versus CDDP and vindesine (VDS) versus CPT-11 alone in advanced non-small cell lung cancer (NSCLC), a multicenter phase III study. Proceedings of the 35th Annual Meeting of the American Society of Clinical Oncology; 1999; Atlanta.
22. Niho S, Nagao K, Nishiwaki Y, et al: Randomized multicenter phase III trial of Irinotecan (CPT-11) and cisplatin (CDDP) versus CDDP and vindesine (VDS) in patients with advanced non-small cell lung cancer (NSCLC). Proceedings of the 35th Annual Meeting of the American Society of Clinical Oncology; 1999; Atlanta.
23. Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98.
24. Kelly K, Crowley J, Bunn PA Jr, et al: Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001;19:3210-3218.
25. Thompson D, Hainsworth J, Burris H, et al: prospective randomized study of four third generation chemotherapy regimens in patients (pts) with advanced non-small cell lung cancer: a Minnie Pearl Cancer Research Network trial. Proceedings of the 37th Annual Meeting of the American Society of Clinical Oncology; 2001; San Francisco.
26. Comella G, Comella P, Frasci G, et al: Cisplatin-gemcitabine, vs. cisplatin-gemcitabine-vinorelbine, vs. cisplatin-gemcitabine-paclitaxel in advanced non-small-cell lung cancer. first-stage analysis of a Southern Italy Cooperative Oncology Group (SICOG) phase III trial. Proceedings of the 36th Annual Meeting of the American Society of Clinical Oncology; 2000; San Francisco.
27. Kosmidis P, Mylonakis N, Nicolaides C, et al: Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 2002;20:3578-3585.
28. van Meerbeeck J, Smit E, Lianes P, et al: A EORTC randomized phase III trial of three chemotherapy regimens in advanced non-small cell lung cancer (NSCLC). Proceedings of the 37th Annual Meeting of the American Society of Clinical Oncology; 2001; San Francisco.
29. Rodriguez J, Pawel J, Pluzanska A, et al: A multicenter, randomized phase III study of docetaxel + cisplatin (DC) and docetaxel + carboplatin (DCB) vs. vinorelbine+cisplatin (VC) in chemotherapy-naive patients with advanced and metastatic non-small cell lung cancer. Proceedings of the 37th Annual Meeting of the American Society of Clinical Oncology; 2001; San Francisco.
30. Fossella FV, Lee JS, Shin DM, et al: Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. J Clin Oncol 1995;13:645-651.
31. Fossella F, DeVore R, Kerr R, et al: Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000;18:2354-2362.
32. Shepherd F, Dancey J, Ramlau R, et al: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2098-2103.
33. Sweeney CJ, Zhu J, Sandler AB, et al: Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a phase II trial in patients with metastatic nonsmall cell lung carcinoma. Cancer 2001;92:2639-2647.
34. Billingham LJ, Cullen MH: The benefits of chemotherapy in patient subgroups with unresectable non-small-cell lung cancer. Ann Oncol 2001;12:1671-1675.
35. Anderson H, Hopwood P, Stephens RJ, et al: Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer-a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-small cell lung cancer. Br J Cancer 2000;83:447-453.
36. Hainsworth JD, Burris H, Greco FA: Weekly docetaxel as a single agent and in combination with gemcitabine in elderly and poor performance status patients with advanced non-small cell lung cancer. Semin Oncol 2001;28(3 Suppl 9):21-25.
37. Gridelli C, Perrone F, Gallo C, et al: Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 2003;95:362-372.
38. Smith IE, O'Brien ME, Talbot DC, et al: Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol 2001;19:1336-1343.
39. Depierre A, Quoix E, Mercier M, et al: Maintenance chemotherapy in advanced non-small cell lung cancer (NSCLC): a randomized study of vinorelbine (V) versus observation (OB) in patients (Pts) responding to induction therapy (French Cooperative Oncology Group). Proceedings of the 37th Annual Meeting of the American Society of Clinical Oncology; 2001; San Francisco.
40. Socinski M, Schell M, Peterman A, et al: Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol 2002;20:1335-1343.
41. Fukuoka M, Yano S, Giaccone G, et al: Final results from a phase II trial of ZD1839 ('Iressa') for patients with advanced non-small-cell lung cancer (IDEAL 1). Proceedings of the 38th Annual Meeting of the American Society of Clinical Oncology; 2002; Orlando.
42. Kris M, Natale R, Herbst R, et al: A phase II trial of ZD1839 ('Iressa') in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum- and docetaxel-based regimens (IDEAL 2). Proceedings of the 38th Annual Meeting of the American Society of Clinical Oncology; 2002; Orlando.
43. Johnson D, Herbst R, Giaccone G, et al: ZD1839 ("Iressa") in combination with paclitaxel and carboplatin in chemotherapy-naive patients with advanced non-small cell lung cancer: results from a phase III clinical trial (INTACT 2). Ann Oncol 2002;13 Suppl 5:127.
44. Giaccone G, Johnson D, Manegold C, et al: A phase III clinical trial of ZD1839 ('Iressa') in combination with gemcitabine and cisplatin in chemotherapy-naive patients with advanced non-small cell lung cancer (INTACT 1). Ann Oncol 2002;13(Suppl 5):2.
45. Perez-Soler R, Chachoua A, Huberman M, et al: A phase ii trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients (pts) with advanced, EGFR-expressing, non-small cell lung cancer (NSCLC). Proceedings of the 37th Annual Meeting of the American Society of Clinical Oncology; 2001; San Francisco.
46. Kim E, Mauer A, Fossella F, et al: A phase II study of erbitux (IMC-C225), an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer (NSCLC). Proceedings of the 38th Annual Meeting of the American Society of Clinical Oncology; 2002; Orlando.
47. Langer C, Adak S, Thor A, et al: Phase II Eastern Cooperative Oncology Group (ECOG) pilot study ofpaclitaxel (P), carboplatin (C), and trastuzumab (T) in HER-2/neu (+) advanced non-small cell lung cancer (NSCLC): early analysis of E2598. Proceedings of the 37th Annual Meeting of the American Society of Clinical Oncology 2001 San Francisco.
48. DeVore R, Fehrenbacher L, Herbst R: A randomized phase II trial comparing rhumab VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIB/IV NSCLC. Proceedings of the 36th Annual Meeting of the American Society of Clinical Oncology; 2000; San Francisco.
49. LCSG: The benefit of adjuvant treatment for resected locally advanced NSCLC. J Clin Oncol 1988;6:9-17.
50. Keller S, Adak S, Wagner H, et al: A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group. N Engl J Med 2000;343:1217-1222.
51. Ohta M, Tsuchiya R, Shimoyama M, et al: Adjuvant chemotherapy for completely resected stage III non-small-cell lung cancer. Results of a randomized prospective study. The Japan Clinical Oncology Group. J Thorac Cardiovasc Surg 1993;106:703-708.
52. Depierre A, Milleron B, Moro-Sibilot D, et al: Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer [comment]. J Clin Oncol 2002;20:247-253.
53. Rosell R, Gomez-Codina J, Camps C, et al: A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small cell lung cancer. N Engl J Med 1994;330:153-158.
54. Roth JA, Fossella F, Komaki R, et al: A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst 1994;86:673-680.
55. Jeremic B, Shibamoto Y, Acimovic L, et al: Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for Stage III non-small-cell lung cancer (NSCLC): a randomized study. J Clin Oncol 1996;14:1065-1070.
56. Le Chevalier T, Arriagada R, Quoix E, et al: Radiotherapy alone versus combined chemotherapy and radiotherapy in non-resectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst 1991;83:417-423.
57. Dillman RO, Seagren SL, Propert KJ, et al: A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 1990;323:940-945.
58. Sause W, Kolesar P, Taylor SI, et al: Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 2000;117:358-364.
59. Choy H, Curran W, Scott W, et al: Preliminary report of locally advanced multimodality protocol (LAMP): ACR 427: a randomized phase II study of three chemo-radiation regimens with paclitaxel, carboplatin, and thoracic radiation (TRT) for patients with locally advanced non small cell lung cancer (LA-NSCLC). Proceedings of the 38th Annual Meeting of the American Society of Clinical Oncology; 2002; Orlando.
60. Vokes E, Leopold K, Herndon J, et al: A randomized phase II study of gemcitabine or paclitaxel or vinorelbine with cisplatin as induction chemotherapy (Ind CT) and concomitant chemoradiotherapy (XRT) for unresectable stage III non-small cell lung cancer (NSCLC) (CALGB Study 9431). Proceedings of the 35th Annual Meeting of the American Society of Clinical Oncology; 1999; Atlanta.
61. Silvestri G, Pritchard R, Welch HG: Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews. BMJ 1998;317(7161):771-775.
62. Hainsworth JD, Gray JR, Morrissey LH, et al: Long-term follow-up of patients treated with paclitaxel/carboplatin-based chemotherapy for advanced non-small-cell lung cancer: sequential phase II trials of the Minnie Pearl Cancer Research Network. J Clin Oncol 2002;20:2937-2942.